# A Randomized-Withdrawal Phase 3 Study Evaluating the Safety and Efficacy of Oral Nalfurafine HCl (AC-820)in Subjects on Hemodialysis With Uremic Pruritus (Renal Itch)

> **NCT00793156** · PHASE3 · UNKNOWN · sponsor: **Acologix, Inc.** · enrollment: 350 (estimated)

## Conditions studied

- Uremic Pruritus

## Interventions

- **DRUG:** Nalfurafine HCl 2.5 µg
- **DRUG:** Nalfurafine HCl 5.0 µg
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00793156
- **Lead sponsor:** Acologix, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-12
- **Primary completion:** 2010-12
- **Final completion:** 2011-03
- **Target enrollment:** 350 (ESTIMATED)
- **Last updated:** 2010-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00793156

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00793156, "A Randomized-Withdrawal Phase 3 Study Evaluating the Safety and Efficacy of Oral Nalfurafine HCl (AC-820)in Subjects on Hemodialysis With Uremic Pruritus (Renal Itch)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00793156. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*